Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 7563705, 6 pages
http://dx.doi.org/10.1155/2016/7563705
Research Article

Homocysteine Levels in Parkinson’s Disease: Is Entacapone Effective?

Department of Neurology, Diskapi Yildirim Beyazit Training and Research Hospital, 06110 Ankara, Turkey

Received 20 March 2016; Revised 29 May 2016; Accepted 15 June 2016

Academic Editor: Mahendra P. Singh

Copyright © 2016 Bilge Kocer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. J. Boushey, S. A. A. Beresford, G. S. Omenn, and A. G. Motulsky, “A quantitative assessment of plasma homocysteine as a risk factor for vascular disease probable benefits of increasing folic acid intakes,” Journal of the American Medical Association, vol. 274, no. 13, pp. 1049–1057, 1995. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Seshadri, A. Beiser, J. Selhub et al., “Plasma homocysteine as a risk factor for dementia and Alzheimer's disease,” The New England Journal of Medicine, vol. 346, no. 7, pp. 476–483, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Zoccolella, D. Martino, G. Defazio, P. Lamberti, and P. Livrea, “Hyperhomocysteinemia in movement disorders: current evidence and hypotheses,” Current Vascular Pharmacology, vol. 4, no. 3, pp. 237–243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Isobe, T. Abe, and Y. Terayama, “L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease,” Journal of Clinical Neuroscience, vol. 17, no. 6, pp. 717–721, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Martignoni, C. Tassorelli, G. Nappi, R. Zangaglia, C. Pacchetti, and F. Blandini, “Homocysteine and Parkinson's disease: a dangerous liaison?” Journal of the Neurological Sciences, vol. 257, no. 1-2, pp. 31–37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Müller, H. Hefter, R. Hueber et al., “Is levodopa toxic?” Journal of Neurology, vol. 251, supplement 6, pp. vi44–vi46, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Zoccolella, P. Lamberti, G. Iliceto et al., “Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias,” Clinical Chemistry and Laboratory Medicine, vol. 44, no. 7, pp. 863–866, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. R. M. Camicioli, T. P. Bouchard, and M. J. Somerville, “Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients,” Movement Disorders, vol. 24, no. 2, pp. 176–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Nissinen, H. Nissinen, H. Larjonmaa et al., “The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats,” Journal of Neural Transmission, vol. 112, no. 9, pp. 1213–1221, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Valkovič, J. Benetin, P. Blažíček, L. Valkovičová, K. Gmitterová, and P. Kukumberg, “Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients,” Parkinsonism and Related Disorders, vol. 11, no. 4, pp. 253–256, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Lamberti, S. Zoccolella, G. Iliceto et al., “Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients,” Movement Disorders, vol. 20, no. 1, pp. 69–72, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Zoccolella, P. Lamberti, E. Armenise et al., “Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications,” Parkinsonism and Related Disorders, vol. 11, no. 2, pp. 131–133, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. P. E. O'Suilleabhain, T. Bottiglieri, R. B. Dewey Jr., S. Sharma, and R. Diaz-Arrastia, “Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease,” Movement Disorders, vol. 19, no. 12, pp. 1403–1408, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. J. L. Ostrem, G. A. Kang, I. Subramanian et al., “The effect of entacapone on homocysteine levels in Parkinson disease,” Neurology, vol. 64, no. 8, p. 1482, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. T. A. Zesiewicz, L. Wecker, K. L. Sullivan, L. R. Merlin, and R. A. Hauser, “The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status,” Clinical Neuropharmacology, vol. 29, no. 3, pp. 106–111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, “Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases,” Journal of Neurology Neurosurgery and Psychiatry, vol. 55, no. 3, pp. 181–184, 1992. View at Publisher · View at Google Scholar · View at Scopus
  17. M. M. Hoehn and M. D. Yahr, “Parkinsonism: onset, progression, and mortality,” Neurology, vol. 17, no. 5, pp. 427–442, 1967. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Fahn, R. L. Elton, and UPDRS Development Committee, “Unified Parkinson's disease rating scale,” in Recent Developments in Parkinson's Disease II, S. Fahn, C. D. Marsden, D. B. Calne, and M. Goldstein, Eds., pp. 153–163, Macmillan, New York, NY, USA, 1987. View at Google Scholar
  19. B. Vester and K. Rasmussen, “High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum,” European Journal of Clinical Chemistry and Clinical Biochemistry, vol. 29, no. 9, pp. 549–554, 1991. View at Google Scholar · View at Scopus
  20. American Society of Human Genetics/American College of Medical Genetics Test and Transfer Committee Working Group, “Measurement and use of total plasma homocysteine,” American Journal of Human Genetics, vol. 63, no. 5, pp. 1541–1543, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. J. J. Genest Jr., J. R. McNamara, B. Upson et al., “Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 11, no. 5, pp. 1129–1136, 1991. View at Publisher · View at Google Scholar · View at Scopus
  22. M. S. Morris, P. F. Jacques, I. H. Rosenberg et al., “Serum total homocysteine concentration is related to self-reported heart attack or stroke history among men and women in the NHANES III,” Journal of Nutrition, vol. 130, no. 12, pp. 3073–3076, 2000. View at Google Scholar · View at Scopus
  23. J. Selhub, P. F. Jacques, A. G. Bostom et al., “Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis,” The New England Journal of Medicine, vol. 332, no. 5, pp. 286–291, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Shenkin and N. B. Roberts, “Vitamins and trace elements,” in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, C. A. Burtis, E. R. Ashwood, and D. E. Bruns, Eds., p. 924, Elsevier, St Louis, Mo, USA, 5th edition, 2012. View at Google Scholar
  25. P. Allain, A. Le Bouil, E. Cordillet, L. Le Quay, H. Bagheri, and J. L. Montastruc, “Sulfate and cysteine levels in the plasma of patients with Parkinson's disease,” NeuroToxicology, vol. 16, no. 3, pp. 527–529, 1995. View at Google Scholar · View at Scopus
  26. T. Müller, B. Werne, B. Fowler, and W. Kuhn, “Nigral endothelial dysfunction, homocysteine, and Parkinson's disease,” The Lancet, vol. 354, no. 9173, pp. 126–127, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Nevrly, P. Kanovsky, H. Vranova, K. Langova, and P. Hlustik, “Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients,” Neurological Sciences, vol. 31, no. 5, pp. 565–569, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Müller and S. Muhlack, “Peripheral COMT inhibition prevents levodopa associated homocysteine increase,” Journal of Neural Transmission, vol. 116, no. 10, pp. 1253–1256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. R. B. Postuma, A. J. Espay, C. Zadikoff et al., “Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A Randomized Controlled Study,” Neurology, vol. 66, no. 12, pp. 1941–1943, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Hassin-Baer, O. Cohen, E. Vakil et al., “Plasma homocysteine levels and parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications,” Clinical Neuropharmacology, vol. 29, no. 6, pp. 305–311, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Zoccolella, P. Lamberti, G. Iliceto et al., “Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions,” Clinical Chemistry and Laboratory Medicine, vol. 43, no. 10, pp. 1107–1110, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. P. E. O'Suilleabhain, V. Sung, C. Hernandez et al., “Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations,” Archives of Neurology, vol. 61, no. 6, pp. 865–868, 2004. View at Publisher · View at Google Scholar · View at Scopus